Inecalcitol, an analog of 1α,25(OH) 2D 3, induces growth arrest of androgen-dependent prostate cancer cells

International Journal of Cancer

Volumn 130, Issue 10, 2012, Pages 2464-2473

  Okamoto, Ryoko ^a   Delansorne, Remi ^b   Wakimoto, Naoki ^a   Doan, Ngan B ^a   Akagi, Tadayuki ^a   Shen, Michelle ^a   Ho, Quoc H ^a   Said, Jonathan W ^a   Koeffler, H Phillip ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Hybrigenics SA   (France)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

antiproliferative effects; inecalcitol; prostate cancer; vitamin D

Indexed keywords

ANDROGEN; CALCITRIOL; CALCIUM; INECALCITOL; MESSENGER RNA; PROTEIN KINASE PIM 1; TRANSCRIPTION FACTOR ETS 1;

ANDROGEN DEPENDENT PROSTATE CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SIZE; CANCER TISSUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPERCALCEMIA; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

ALKYNES; ANDROGENS; ANIMALS; CELL LINE, TUMOR; CHOLECALCIFEROL; HUMANS; MALE; MICE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859104276     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26279     Document Type: Article

References (32)

1. Jemal A, Ward E, Thun M,. Declining death rates reflect progress against cancer. PLoS One 2010; 5: e9584.
2. Guzey M, Kitada S, Reed J,. Apoptosis induction by 1alpha,25- dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002; 1: 667-77.
3. Bao B, Hu Y, Ting H, Lee Y,. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene 2004; 23: 3350-60. (Pubitemid 38669824)
4. Yang E, Burnstein K,. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003; 278: 46862-8. (Pubitemid 37452267)
5. Polek T, Stewart L, Ryu E, Cohen M, Allegretto E, Weigel N,. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 2003; 144: 50-60. (Pubitemid 36076092)
6. Nonn L, Peng L, Feldman D, Peehl D,. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res 2006; 66: 4516-24.
7. Verlinden L, Verstuyf A, Van Camp M, Marcelis S, Sabbe K, Zhao X, De Clercq P, Vandewalle M, Bouillon R,. Two novel 14-epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 2000; 60: 2673-9. (Pubitemid 30318243)
8. Amaravadi R, Thompson CB,. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115: 2618-24. (Pubitemid 41434384)
9. Dhanasekaran S, Barrette T, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta K, Rubin M, Chinnaiyan A,. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-6. (Pubitemid 32801464)
10. Shah N, Pang B, Yeoh K, Thorn S, Chen C, Lilly M, Salto-Tellez M,. Potential roles for the PIM1 kinase in human cancer-a molecular and therapeutic appraisal. Eur J Cancer 2008; 44: 2144-51.
11. Roh M, Gary B, Song C, Said-Al-Naief N, Tousson A, Kraft A, Eltoum I, Abdulkadir S,. Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res 2003; 63: 8079-84. (Pubitemid 37549449)
12. Roh M, Franco O, Hayward S, van der Meer R, Abdulkadir S,. A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells. PLoS One 2008; 5: e9584.
13. Kumar-Sinha C, Tomlins S, Chinnaiyan A,. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497-511.
14. Gasi D, van der Korput HA, Douben HC, de Klein A, de Ridder CM, van Weerden WM, Trapman J,. Overexpression of Full-Length ETV1 Transcripts in Clinical Prostate Cancer Due to Gene Translocation. PLoS One 2011; 5: e9584.
15. Cai C, Hsieh C, Omwancha J, Zheng Z, Chen S, Baert J, Shemshedini L,. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 2007; 21: 1835-46. (Pubitemid 47173795)
16. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren J, Bokesch H, Kenney S, Boyd M,. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-12. (Pubitemid 20213250)
17. Munker R, Kobayashi T, Elstner E, Norman A, Uskokovic M, Zhang W, Andreeff M, Koeffler H,. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 1996; 88: 2201-9. (Pubitemid 26307923)
18. O'Kelly J, Uskokovic M, Lemp N, Vadgama J, Koeffler H,. Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway. J Steroid Biochem Mol Biol 2006; 100: 107-16. (Pubitemid 44175834)
19. Thoennissen N, Iwanski G, Doan N, Okamoto R, Lin P, Abbassi S, Song J, Yin D, Toh M, Xie W, Said J, Koeffler H,. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009; 69: 5876-84.
20. Rostad K, Mannelqvist M, Halvorsen OJ, Oyan AM, Bø TH, Stordrange L, Olsen S, Haukaas SA, Lin B, Hood L, Jonassen I, Akslen LA, et al,. ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol 2007; 30: 19-32.
21. Tomlins S, Laxman B, Dhanasekaran S, Helgeson B, Cao X, Morris D, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, et al,. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448: 595-9. (Pubitemid 47206938)
22. Ikezoe T, Gery S, Yin D, O'Kelly J, Binderup L, Lemp N, Taguchi H, Koeffler H,. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells. Cancer Res 2005; 65: 4762-8. (Pubitemid 40740813)
23. Vegesna V, O'Kelly J, Said J, Uskokovic M, Binderup L, Koeffle HP,. Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer Res 2003; 23: 283-9. (Pubitemid 36358530)
24. Verlinden L, Verstuyf A, Quack M, Van Camp M, Van Etten E, De Clercq P, Vandewalle M, Carlberg C, Bouillon R,. Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements. J Bone Miner Res 2001; 16: 625-38. (Pubitemid 32230591)
25. Eelen G, Verlinden L, Rochel N, Claessens F, De Clercq P, Vandewalle M, Tocchini-Valentini G, Moras D, Bouillon R, Verstuyf A,. Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Mol Pharmacol 2005; 67: 1566-73. (Pubitemid 40594155)
26. Olivera CJ, Bula CM, Bishop JE, Adorini L, Manchand P, Uskokovic MR, Norman AW,. Characterization of five 19-nor-analogs of 1alpha,25(OH)2-Vitamin D3 with 20-cyclopropyl-modified side-chains: implications for ligand binding and calcemic properties. J Steroid Biochem Mol Biol 2004; 89-90: 99-106. (Pubitemid 38844267)
27. Muindi JR, Modzelewski RA, Peng Y, Trump DL, Johnson CS,. Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology 2004; 66: 62-6. (Pubitemid 38410681)
28. Papapoulos SE, Clemens TL, Sandler LM, Fraher LJ, Winer J, O'Riordan JL,. The effect of renal function on changes in circulating concentrations of 1,25-dihydroxycholecalciferol after an oral dose. Clin Sci (Lond) 1982; 62: 427-9. (Pubitemid 12117728)
29. Thorne JL, Maguire O, Doig CL, Battaglia S, Fehr L, Sucheston LE, Heinaniemi M, O'Neill LP, McCabe CJ, Turner BM, Carlberg C, Campbell MJ,. Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res 2011; 39: 2045-56.
30. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y,. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the. Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 1999; 274: 18659-66.
31. Bachmann M, Hennemann H, Xing P, Hoffmann I, Möröy T,. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 2004; 279: 48319-28. (Pubitemid 39540988)
32. Wang Z, Bhattacharya N, Mixter P, Wei W, Sedivy J, Magnuson N,. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002; 1593: 45-55. (Pubitemid 35335911)